RxDoctor Payments Data

Hamid Salehi, MD

Neurology · Mission Viejo, CANPI 1992733257

Payments from drug & device makers

$8,195in general payments, 2019–2025

Across 413 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$739
  • UCB, Inc.$655
  • Acadia Pharmaceuticals Inc$492
  • Lilly USA, LLC$489
  • Supernus Pharmaceuticals, Inc.$350
  • plus $4K from 37 others

What the payments were for

  • Speaking & faculty fees$300%
  • Food & beverage$8,11699%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,195 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$472,662
Medicare patients
589
Services billed
3,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5023$321,165
NuplazidPimavanserin Tartrate35$226,543
RexultiBrexpiprazole38$73,172
NamzaricMemantine Hcl/Donepezil Hcl17$26,626
Memantine Hcl345$10,523
Galantamine Hbr91$9,508
NeuproRotigotine11$9,082
Oxtellar XrOxcarbazepine13$7,757
Donepezil Hcl546$5,016
Carbidopa-LevodopaCarbidopa/Levodopa148$4,426
Carbidopa-Levodopa ErCarbidopa/Levodopa41$3,739
Ropinirole Hcl104$2,826
Rivastigmine18$2,734
Levetiracetam89$2,701
Gabapentin153$2,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$72$321,16523 claims
Acadia Pharmaceuticals IncNuplazid$492$226,54335 claims
Otsuka America Pharmaceutical, Inc.Rexulti$26$73,17238 claims
AbbVieNamzaric$1,922$26,62617 claims
UCB, Inc.Neupro$655$9,08211 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$350$7,75713 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$192$1,64519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →